Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

Merck Sharp & Dohme LLC1,500 enrolled

Overview

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

1,500

Conditions

Chemotherapy Induced Nausea and Vomiting

Interventions

Disease Management AssessmentBEHAVIORAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Highly or moderately emetogenic chemotherapy planned for at least 2 cycles Exclusion Criteria: * Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis

Outcomes

Primary Outcomes

CINV at the delayed phase during cycle 2

Secondary Outcomes

Treatment for CINV

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.